Publication|Articles|May 1, 2003

May 2003
Volume 9
Issue 5

Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience

Author(s)Darren Kocs, MD, MHSA, A. Mark Fendrick, MD

Download PDF: Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience

Articles in this issue

about 23 years ago

Article

Lansoprazole Overutilization: Methods for Step-Down Therapy

about 23 years ago

Article

Reducing Costs and Improving Outcomes of Percutaneous Coronary Interventions

about 23 years ago

Article

Evaluation of a Depression Health Management Program to Improve Outcomes in First or Recurrent Episode Depression

about 23 years ago

Article

A Prediction Model for Targeting Low-Cost, High-Risk Members of Managed Care Organizations

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Timing and Characteristics of Supplemental Indications for Medicines

ByYingying Zhu, PhD,Claire H. Brennan, BA,Haijun Tian, PhD,Josephine N. Tran, PharmD, MS,Peter J. Neumann, ScD,James D. Chambers, PhD,Pei-Jung Lin, PhD,Meng Li, PhD

July 6th 2026

State Medicaid Budgetary Implications of New Cancers

ByAmanda C. Chen, PhD,Anuraag R. Kansal, PhD,David C. Grabowski, PhD

July 2nd 2026

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

ByKaitlyn T. Haas, PharmD,Joseph J. Saseen, PharmD, BCPS, BCACP,Oliver Titus, MS,Nathan Lamberton, PharmD, BCACP,Lisa M. Schilling, MD, MSPH,Keri N. Hogan, PharmD, BCACP,Alison Marks, BA,Sarah J. Billups, PharmD, BCPS

July 1st 2026

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience

Articles in this issue

Related Content

The Timing and Characteristics of Supplemental Indications for Medicines

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Trending on AJMC

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience

Articles in this issue

Related Content

The Timing and Characteristics of Supplemental Indications for Medicines

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Trending on AJMC

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure